The Swiss Debiopharm Group and US-based Ascenta Therapeutics have entered into an exclusive worldwide license development and commercialisation agreement for the Phase I compound, AT-406 (also, Debio 1143) for the treatment of various cancers.
The drug is an orally available small molecule that works by targeting IAP (inhibitor of Apoptosis Proteins). Most current cancer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
